Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2020-01-15 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-01-15 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-14 English
FORM 10-K/A
Annual Report FY 2019
2020-01-10 English
424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement No. 1 to Reoffer Prospectus' filed pursuant to Rule 424(b)(3) under the Securities Act, related to the resale of common stock by selling stockholders under various stock incentive plans. It details the number of shares held and offered for resale by company insiders and directors. This type of filing is a supplement to a registration statement and is primarily about share resale by insiders, which is a capital market transaction related to share issuance and resale. It is not an annual report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. It is a capital/financing update related to share registration and resale by insiders. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about share offerings and selling stockholders, confirming it is not a mere announcement but a substantive filing about capital structure changes.
2020-01-09 English
FORM 10-K
Annual Report FY 2019
2020-01-09 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-16 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.